Table 2.
Neutralization titer against HIV-1 clinical isolates in BALB/c mice
| Vaccine groups | Neutralization titer against HIV-1 isolates | |||||
|---|---|---|---|---|---|---|
| XJDC6371 | XJDC6431 | XJDC0793 | CBJB105 | CBJB248 | 020101300 | |
| SV145 | < 6 | < 6 | < 6 | < 6 | < 6 | > 12 |
| SV145-10M | > 12 | > 24 | > 24 | > 24 | > 24 | > 12 |
| SV145M1&2 | < 6 | > 24 | > 24 | > 24 | > 24 | > 24 |
| SV145M1 | < 6 | > 24 | > 24 | > 24 | > 24 | > 24 |
| SV145M2 | < 6 | > 12 | > 12 | > 12 | > 12 | > 12 |
| SV145M3 | < 6 | < 6 | < 6 | < 6 | > 12 | > 12 |
| SV145M4 | < 6 | < 6 | < 6 | < 6 | > 12 | > 12 |
| SV145M5 | < 6 | < 6 | < 6 | < 6 | < 6 | < 6 |
The neutralization was conducted by using a panel of clinical isolates in PBMCs with 50% inhibitory dose. Gp145-10 M, gp145M1&2, gp145M1 and 145M2 groups could neutralize HIV-1 isolates at the highest titer of 1:24, other than XJDC6371. The single N-glycosylation site deletion in the V1 loop designated as gp145M2 could induce broader neutralizing antibodies against five clinical isolates at a titer of 1:12.